Last updated July 12, 2026
Key finding
TIR increased from 26.4% at baseline to 52.7% at Week 16.
The study evaluated the impact of iGlarLixi on treatment satisfaction in adults with Type 2 Diabetes, showing improvements in satisfaction scores and time in range.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
The study evaluated the impact of iGlarLixi on treatment satisfaction in adults with Type 2 Diabetes, showing improvements in satisfaction scores and time in range.
Improving treatment satisfaction is crucial for individuals managing Type 2 Diabetes, as it can lead to better adherence to medication regimens and improved health outcomes. The findings suggest that iGlarLixi may enhance patients' experiences and control over their diabetes, which is vital for long-term management.
The study design was non-randomized, which may introduce bias. Effectiveness data were reported as unclear for several outcomes. Sample size and demographic details were not specified.
Published in
Publication details and source links for this paper.
Viral NS, Terry D, Luigi M, Amélie R, William HP. Treatment with iGlarLixi Improves Treatment Satisfaction in Adults with Type 2 Diabetes. Diabetes, Obesity & Metabolism. 2025;27(5):2523-2530. doi:10.1111/dom.16251
Time in range (TIR) increased from 26.4% at baseline to 52.7% at Week 16.
Overall treatment satisfaction score improved by 0.18, from 0.59 at baseline to 0.78 at Week 16.
The largest increase in treatment satisfaction was observed in the medical control domain.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) and Time in range, Treatment satisfaction.
This study contributes evidence to
Primary intervention
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi)
Primary outcomes
Evidence topics
Primary intervention
Primary outcomes
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
2
Related topics
2
Evidence pairs
263
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
Related evidence
Evidence relationship
Save evidence
Evidence topic
Save evidence
Core evidence
The primary outcomes reported in this study.
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) → Time in range
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) → Time in range
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) → Treatment satisfaction
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) → Treatment satisfaction
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Insulin Therapies and CGM Time in Range, Insulin Therapies and Treatment Experience.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Medications
Curated evidence collections and hubs this study is part of.
All studies measuring CGM Time in Range
Measures CGM Time in Range as a key outcome.
All studies on Insulin Therapies
Contributes to Insulin Therapies evidence base.
All studies measuring Treatment Experience
Measures Treatment Experience as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
2 results
1 results
2 results
2 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
Insulin Therapies may improve CGM Time in Range.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
Time in range
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 9 supporting studies with generally consistent results and a positive effect signal.
Limitations
Insulin Therapies appears to improve Treatment Experience.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Treatment satisfaction
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a small number of supporting studies and should be interpreted cautiously.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
